| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human CD300A recombinant protein (Position: L156-T299) was used as the immunogen for the CD300A antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
CD300A Antibody is a anti-CD300A Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), Flow cytometry (FACS), ELISA with listed reactivity in Human, Mouse, Rat.
Key elements and design rationale
- Target: CD300A
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, FACS, ELISA
Biological background
Structurally, CD300A possesses multiple immunoreceptor tyrosine-based inhibitory motifs (ITIMs) within its cytoplasmic tail. Upon ligand engagement, these motifs recruit phosphatases such as SHP-1 and SHP-2, which dephosphorylate signaling intermediates and suppress proinflammatory responses. This mechanism dampens activation of monocytes, macrophages, mast cells, and NK cells, preventing excessive inflammation and autoimmune reactions. CD300A thereby acts as a negative regulator of immune activation by balancing activating signals from other CD300 family members.
The CD300A antibody is widely used in immunology, inflammation, and autoimmune disease research to study inhibitory receptor signaling, immune regulation, and apoptotic cell clearance. Flow cytometry and western blot analyses detect a 35-40 kilodalton band corresponding to CD300A, while immunohistochemistry shows strong membrane staining on leukocytes and myeloid cells. This antibody supports analysis of inhibitory receptor expression and function in both innate and adaptive immune systems.
Aberrant CD300A expression has been implicated in autoimmune diseases, allergy, and cancer. Increased expression can suppress antitumor immunity, while reduced expression contributes to hyperinflammatory conditions. The CD300A antibody provides a valuable tool for investigating the balance between immune activation and inhibition in health and disease.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- Flow cytometry: quantify target-positive populations and signal shifts at single-cell resolution.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
